Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations

References

• Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect Dis. 2009;28(7):719–30.
   PubMed Web of Science ®Google Scholar
• Crossman L, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 2008;9(4):R74.
   Google Scholar
• Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312–23.
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005;25(2):95–109.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001;32(Suppl 2):S104–13.
   Google Scholar
• Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al. Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents. 2011;37(3):230–4.
   PubMed Web of Science ®Google Scholar
• San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzl M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:168–71.
   PubMed Web of Science ®Google Scholar
• Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother. 2010;16:322–8.
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1.
   PubMed Web of Science ®Google Scholar
• Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther. 2011;9(4):471–88.
   PubMed Web of Science ®Google Scholar
• Chung HS, Hong SG, Lee Y, Kim M, Yong D, Jeong SH, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital. Yonsei Med J. 2012;53(2):439–41.
   PubMed Web of Science ®Google Scholar
• Zhang R, Sun Q, Hu YJ, Yu H, Yi Li, Shen Q, et al. Detection of the Smqnr quinolone protection gene and its prevalence in clinical isolates of Stenotrophomonas maltophilia in China. J Med Microbiol. 2012;61(Pt 4):535–9.
   PubMed Web of Science ®Google Scholar
• Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect. 2004;57(1):1–7.
   PubMed Web of Science ®Google Scholar
• Tatman-Otkun M, Gürcan S, Ozer B, Aydoslu B, Bukavaz S. The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness. BMC Microbiol. 2005;5:24.
   PubMed Web of Science ®Google Scholar
• Neela V, Rankouhi SZ, van Belkum A, Goering RV, Awang R. Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim–sulfamethoxazole resistance. Int J Infect Dis. 2012;16(8):e603–7.
   Google Scholar
• Rhee JY, Choi JY, Choi MJ, Song JH, Peck KR, Ko KS. Distinct groups and antimicrobial resistance of clinical Stenotrophomonas maltophilia complex isolates from Korea. J Med Microbiol. 2013;62(Pt 5):748–53.
   PubMedGoogle Scholar
• Gülmez D, Hasçelik G. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin Microbiol Infect. 2005;11(11):880–6.
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis. 2005;51(1):39–43.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008;62(5):889–94.
   PubMed Web of Science ®Google Scholar
• Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28(1):62–6.
   PubMed Web of Science ®Google Scholar
• Visalli MA, Jacobs MR, Appelbaum PC. Activities of three quinolones, alone an in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1998;42(8):2002–5.
   PubMed Web of Science ®Google Scholar
• Poulos CD, Matsumura SO, Willey BM, Low DE, McGreer A. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother. 1995;39:2220–3.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Guerrini M, Felici A, Marchetti F. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. J Chemother. 2005;17(4):355–60.
   PubMed Web of Science ®Google Scholar
• Nadrah K, Strle F. Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections. Chemother Res Pract. 2011;2011:619321.
   PubMedGoogle Scholar